Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The multiple myeloma cell line RPMI-8226, which expresses high levels of CD138 and contains a typical small subpopulation of CD138high cells (S5 Fig), as reported previously [29,30], served as positive control.”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
Bharadwaj, S., Liu, G., Shi, Y., Wu, R., Yang, B., He, T., Fan, Y., Lu, X., Zhou, X., Liu, H., et al. (2013) · Stem Cells · doi:10.1002/stem.1424 · Cited by 322 · cited 1×
“Since differentiation potential is a characteristic of stem cells [30], we wanted to know if CD138 cells give rise to CD138 cells or vice versa.”
Background
Research works printed but not linked: 48
- JF San-Miguel, 2011, Can multiple myeloma become a curable disease, Haematologica, 96, 1246, 10.3324/haematol.2011.051169 · DOI
- A Hamburger, 1977, Primary bioassay of human myeloma stem cells, J Clin Invest, 60, 846, 10.1172/JCI108839 · doi:10.1172/jci108839
- M Chilosi, 1999, CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies, Mod Pathol, 12, 1101
- A Wei, 2003, Bone marrow immunohistology of plasma cell neoplasms, J Clin Pathol, 56, 406, 10.1136/jcp.56.6.406 · DOI
- J Wijdenes, 1996, A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, Br J Haematol, 94, 318, 10.1046/j.1365-2141.1996.d01-1811.x · DOI · Paper page
- G Jego, 1999, Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, Blood, 94, 701, 10.1182/blood.V94.2.701 · DOI · Paper page
- G Jego, 2001, Interleukin-6 is a growth factor for nonmalignant human plasmablasts, Blood, 97, 1817, 10.1182/blood.V97.6.1817 · DOI · Paper page
- KL Calame, 2001, Plasma cells: finding new light at the end of B cell development, Nat Immunol, 2, 1103, 10.1038/ni1201-1103 · DOI · Paper page
- W Matsui, 2004, Characterization of clonogenic multiple myeloma cells, Blood, 103, 2332, 10.1182/blood-2003-09-3064 · DOI · Paper page
- W Matsui, 2008, Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance, Cancer Res, 68, 190, 10.1158/0008-5472.CAN-07-3096 · DOI · Paper page
- K Boucher, 2012, Stemness of B-cell progenitors in multiple myeloma bone marrow, Clin Cancer Res, 18, 6155, 10.1158/1078-0432.CCR-12-0531 · DOI
- K Yata, 2004, The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells, Leukemia, 18, 1891, 10.1038/sj.leu.2403513 · DOI
- D Chiron, 2012, The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients, Br J Haematol, 156, 679, 10.1111/j.1365-2141.2011.08904.x · DOI
- D Kim, 2012, CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells, Leukemia, 26, 2530, 10.1038/leu.2012.140 · DOI
- A Kukreja, 2006, Enhancement of clonogenicity of human multiple myeloma by dendritic cells, J Exp Med, 203, 1859, 10.1084/jem.20052136 · DOI · Paper page
- GM Fuhler, 2010, Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells, Exp Cell Res, 316, 1816, 10.1016/j.yexcr.2010.03.013 · DOI
- JH Christensen, 2012, Characterization of potential CD138 negative myeloma “stem cells”, Haematologica, 97, e18, 10.3324/haematol.2011.043125 · doi:10.3324/haematol.2011.043125
- S Greenstein, 2003, Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells, Exp Hematol, 31, 271, 10.1016/S0301-472X(03)00023-7 · DOI
- F Sanz-Rodriguez, 1999, Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1, Br J Haematol, 107, 825, 10.1046/j.1365-2141.1999.01762.x · DOI · Paper page
- Q Chen, 2005, The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells, Blood, 106, 698, 10.1182/blood-2004-11-4286 · DOI · Paper page
- MH Ma, 2003, The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents, Clin Cancer Res, 9, 1136
- B Paiva, 2011, Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma, Leukemia, 25, 697, 10.1038/leu.2010.320 · DOI
- X Carvajal-Vergara, 2005, Multifunctional role of Erk5 in multiple myeloma, Blood, 105, 4492, 10.1182/blood-2004-08-2985 · DOI
- NC Gutierrez, 2005, Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia, Leukemia, 19, 402, 10.1038/sj.leu.2403625 · DOI · Paper page
- JJ van Dongen, 2003, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, 17, 2257, 10.1038/sj.leu.2403202 · DOI · Paper page
- EM Ocio, 2009, Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks, Blood, 113, 3781, 10.1182/blood-2008-09-177774 · DOI
- S Zhou, 2001, The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype, Nat Med, 7, 1028, 10.1038/nm0901-1028 · DOI · Paper page
- L Li, 2011, Stem cell quiescence, Clin Cancer Res, 17, 4936, 10.1158/1078-0432.CCR-10-1499 · DOI · Paper page
- E Charafe-Jauffret, 2009, Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer Res, 69, 1302, 10.1158/0008-5472.CAN-08-2741 · DOI · Paper page
- D Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med, 3, 730, 10.1038/nm0797-730 · DOI · Paper page
- N Hosen, 2012, CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients, Leukemia, 26, 2135, 10.1038/leu.2012.80 · DOI
- H Li, 2008, PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells, Cancer Res, 68, 1820, 10.1158/0008-5472.CAN-07-5878 · DOI · Paper page
- A Roesch, 2010, A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth, Cell, 141, 583, 10.1016/j.cell.2010.04.020 · DOI · Paper page
- R Spisek, 2007, Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy, J Exp Med, 204, 831, 10.1084/jem.20062387 · DOI · Paper page
- J Jakubikova, 2011, Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications, Blood, 117, 4409, 10.1182/blood-2010-02-267344 · DOI
- S Yaccoby, 2005, The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype, Clin Cancer Res, 11, 7599, 10.1158/1078-0432.CCR-05-0523 · DOI
- J Jacak, 2013, Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout, J Biotechnol, 164, 525, 10.1016/j.jbiotec.2013.01.027 · doi:10.1016/j.jbiotec.2013.01.027
- A Chaidos, 2013, Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma, Blood, 121, 318, 10.1182/blood-2012-06-436220 · DOI · Paper page
- T Reya, 2001, Stem cells, cancer, and cancer stem cells, Nature, 414, 105, 10.1038/35102167 · DOI · Paper page
- LV Nguyen, 2012, Cancer stem cells: an evolving concept, Nat Rev Cancer, 12, 133, 10.1038/nrc3184 · DOI · Paper page
- S Reid, 2010, Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma, Int J Lab Hematol, 32, e190, 10.1111/j.1751-553X.2010.01222.x · DOI
- GG Wulf, 2001, A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia, Blood, 98, 1166, 10.1182/blood.V98.4.1166 · DOI · Paper page
- Y Luo, 2012, ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets, Stem Cells, 30, 2100, 10.1002/stem.1193 · DOI · Paper page
- JE Dick, 1996, Human stem cell assays in immune-deficient mice, Curr Opin Hematol, 3, 405, 10.1097/00062752-199603060-00002 · DOI
- LM Pilarski, 2000, Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice, Blood, 95, 1056, 10.1182/blood.V95.3.1056.003k26_1056_1065 · DOI
- E Van Valckenborgh, 2012, Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model, Leukemia, 26, 1436, 10.1038/leu.2011.373 · DOI
- T Paino, 2012, CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype, Haematologica, 97, 1110, 10.3324/haematol.2011.057372 · doi:10.3324/haematol.2011.057372
- T Paino, 2013, Reply to “Response to”CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110–1114, Haematologica, 98, e10, 10.3324/haematol.2012.077727 · doi:10.3324/haematol.2012.077727
Cited by
Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009117 · Cited by 31
Metadata
- Authors
- Paíno, T., Sarasquete, M. E., Paiva, B., Krzeminski, P., San-Segundo, L., Corchete, L. A., Redondo, A., Garayoa, M., García-Sanz, R., Gutiérrez, N. C., Ocio, E. M., & San-Miguel, J. F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-21
- Volume
- 9
- Issue
- 3
- Pages
- e92378
- ISSN
- 1932-6203
- Cited by
- 22
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. https://app.cochat.ai/papers/10.1371/journal.pone.0092378
- The paper
- Paíno, T., Sarasquete, M. E., Paiva, B., Krzeminski, P., San-Segundo, L., Corchete, L. A., Redondo, A., Garayoa, M., García-Sanz, R., Gutiérrez, N. C., Ocio, E. M., & San-Miguel, J. F. (2014). Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. PLoS ONE. https://doi.org/10.1371/journal.pone.0092378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.